Daprodustat for anemia: a 24-week, open-label, randomized controlled trial in participants on hemodialysis

Autor: John J. Lepore, Delyth Jones, Borut Cizman, Michael Aarup, Brendan M Johnson, Amy M Meadowcroft, A Kaldun Nossuli, Nandita Biswas, Alexander R. Cobitz, Louis Holdstock

Publikováno v: Meadowcroft, A M, Cizman, B, Holdstock, L, Biswas, N, Johnson, B M, Jones, D, Nossuli, A K, Lepore, J J, Aarup, M & Cobitz, A R 2019, ' Daprodustat for anemia : a 24-week, open-label, randomized controlled trial in participants on hemodialysis ', Clinical Kidney Journal, vol. 12, no. 1, pp. 139-148 . https://doi.org/10.1093/ckj/sfy014
Clinical Kidney Journal

Background: This study evaluated the hemoglobin dose response, other efficacy measures and safety of daprodustat, an orally administered, hypoxia-inducible factor prolyl hydroxylase inhibitor in development for anemia of chronic kidney disease.Method

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::10f63352d41ad3465f10ec3a87b84977
https://doi.org/10.1093/ckj/sfy014

Eltrombopag with gemcitabine‐based chemotherapy in patients with advanced solid tumors: a randomized phase I study

Autor: Conrad Messam, Boguslawa Karaszewska, Donald A. Richards, Rodryg Ramlau, Bhabita Mayer, Kirushna Kumar, Eric S. Winer, Yasser Mostafa Kamel, Frederic Forget, Brendan M. Johnson, Howard Safran, Lee Hartner

Publikováno v: Cancer Medicine

Preventing chemotherapy-induced thrombocytopenia could avoid chemotherapy dose reductions and delays. The safety and maximum tolerated dose of eltrombopag, an oral thrombopoietin receptor agonist, with gemcitabine-based therapy was evaluated. Patient

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed9941b914567d3388495e10b25eb555
https://doi.org/10.1002/cam4.326

A pharmacokinetic, pharmacodynamic, and safety study of intravenous cyclophosphamide with an oral casopitant antiemetic regimen in cancer patients

Autor: Brendan M. Johnson, Laurel M. Adams, Sharon C. Murray

Publikováno v: Clinical Pharmacology in Drug Development. 3:93-100

Casopitant is a potent and selective neurokinin-1 receptor antagonist formerly under development for a number of indications, including the treatment of chemotherapy-induced nausea and vomiting. This study was an open-label, randomized, multi-center,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e0f9ed4c7d14e95f15d392026fd17c93
https://doi.org/10.1002/cpdd.57

Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine

Autor: Monica Fiore, Stefano Zamuner, Michela Peroni, Sofia Fernandes, Sabrina Pagliarusco, Brendan M. Johnson, Laurel M. Adams, Paolo Fina

Publikováno v: British Journal of Clinical Pharmacology. 70:537-546

AIM To evaluate the impact of single and repeated doses casopitant on the pharmacokinetics of single dose midazolam and nifedipine (CYP3A substrates) in healthy subjects. The effect on debrisoquine metabolism (CYP2D6 substrate) was also assessed.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::158cadc6b9d94072299bf0d92412ef6b
https://doi.org/10.1111/j.1365-2125.2010.03729.x

Ketoconazole and Rifampin Significantly Affect the Pharmacokinetics, But Not the Safety or QTc Interval, of Casopitant, a Neurokinin-1 Receptor Antagonist

Autor: Brendan M. Johnson, Laurel M. Adams, Ke Zhang, Shelby D. Gainer, Lyndon C. Kirby, Robert A. Blum, Glen Apseloff, Royce A. Morrison, null MD, Peter F. Lebowitz

Publikováno v: The Journal of Clinical Pharmacology. 50:951-959

Casopitant, an antiemetic, is a neurokinin-1 receptor antagonist metabolized primarily by cytochrome P450 3A4 (CYP3A4). Three phase 1 studies with 131 healthy subjects examined the impact of a strong CYP3A inhibitor (ketoconazole) and inducer (rifamp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::84f30fb18b78111a8065be483c49a873
https://doi.org/10.1177/0091270009353761